Tryptamine Therapeutics Limited
TYPTF
$0.02
$0.007.14%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.00M | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.00M | -- | -- | -- | -- |
| Cost of Revenue | 1.57M | -- | -- | -- | -- |
| Gross Profit | -565.80K | -- | -- | -- | -- |
| SG&A Expenses | 2.77M | -- | -- | -- | 1.77M |
| Depreciation & Amortization | 35.00K | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.37M | -- | -- | -- | 3.01M |
| Operating Income | -3.37M | -- | -- | -- | -3.01M |
| Income Before Tax | -3.49M | -- | -- | -- | -3.55M |
| Income Tax Expenses | -- | -- | -- | -- | 1.70K |
| Earnings from Continuing Operations | -3.49 | -- | -- | -- | -3.56 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.49M | -- | -- | -- | -3.56M |
| EBIT | -3.37M | -- | -- | -- | -3.01M |
| EBITDA | -3.34M | -- | -- | -- | -- |
| EPS Basic | 0.00 | -- | -- | -- | -0.04 |
| Normalized Basic EPS | 0.00 | -- | -- | -- | -0.02 |
| EPS Diluted | 0.00 | -- | -- | -- | -0.04 |
| Normalized Diluted EPS | 0.00 | -- | -- | -- | -0.02 |
| Average Basic Shares Outstanding | 5.51B | -- | -- | -- | 367.41M |
| Average Diluted Shares Outstanding | 5.51B | -- | -- | -- | 367.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |